JP7438604B2 - ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン - Google Patents

ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン Download PDF

Info

Publication number
JP7438604B2
JP7438604B2 JP2022548194A JP2022548194A JP7438604B2 JP 7438604 B2 JP7438604 B2 JP 7438604B2 JP 2022548194 A JP2022548194 A JP 2022548194A JP 2022548194 A JP2022548194 A JP 2022548194A JP 7438604 B2 JP7438604 B2 JP 7438604B2
Authority
JP
Japan
Prior art keywords
mol
mrna
protein
antigen
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022548194A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513544A (ja
JP2023513544A5 (https=
JPWO2021159040A5 (https=
Inventor
ギヨーム・スチュアート－ジョーンズ
サイダ・マーグーブ・エルバシル
アンドレア・カーフィ
ミハイル・メトカー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
ModernaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74845093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7438604(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ModernaTx Inc filed Critical ModernaTx Inc
Publication of JP2023513544A publication Critical patent/JP2023513544A/ja
Priority to JP2023132619A priority Critical patent/JP7443608B2/ja
Publication of JP2023513544A5 publication Critical patent/JP2023513544A5/ja
Publication of JPWO2021159040A5 publication Critical patent/JPWO2021159040A5/ja
Priority to JP2024023916A priority patent/JP7832243B2/ja
Application granted granted Critical
Publication of JP7438604B2 publication Critical patent/JP7438604B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022548194A 2020-02-07 2021-02-06 ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン Active JP7438604B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023132619A JP7443608B2 (ja) 2020-02-07 2023-08-16 ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン
JP2024023916A JP7832243B2 (ja) 2020-02-07 2024-02-20 ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062971825P 2020-02-07 2020-02-07
US62/971,825 2020-02-07
US202063016175P 2020-04-27 2020-04-27
US63/016,175 2020-04-27
US202063044330P 2020-06-25 2020-06-25
US63/044,330 2020-06-25
US202063063137P 2020-08-07 2020-08-07
US63/063,137 2020-08-07
PCT/US2021/016979 WO2021159040A2 (en) 2020-02-07 2021-02-06 Sars-cov-2 mrna domain vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023132619A Division JP7443608B2 (ja) 2020-02-07 2023-08-16 ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン

Publications (4)

Publication Number Publication Date
JP2023513544A JP2023513544A (ja) 2023-03-31
JP2023513544A5 JP2023513544A5 (https=) 2023-08-24
JPWO2021159040A5 JPWO2021159040A5 (https=) 2023-08-24
JP7438604B2 true JP7438604B2 (ja) 2024-02-27

Family

ID=74845093

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022548194A Active JP7438604B2 (ja) 2020-02-07 2021-02-06 ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン
JP2023132619A Active JP7443608B2 (ja) 2020-02-07 2023-08-16 ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン
JP2024023916A Active JP7832243B2 (ja) 2020-02-07 2024-02-20 ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023132619A Active JP7443608B2 (ja) 2020-02-07 2023-08-16 ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン
JP2024023916A Active JP7832243B2 (ja) 2020-02-07 2024-02-20 ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン

Country Status (11)

Country Link
US (1) US20230346914A1 (https=)
EP (1) EP4100052A2 (https=)
JP (3) JP7438604B2 (https=)
KR (1) KR20220140528A (https=)
CN (1) CN115551545A (https=)
AU (1) AU2021215938A1 (https=)
BR (1) BR112022015565A2 (https=)
CA (1) CA3170150A1 (https=)
IL (1) IL295377A (https=)
MX (1) MX2022009707A (https=)
WO (1) WO2021159040A2 (https=)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
TW201729835A (zh) 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
HRP20220652T1 (hr) 2015-12-10 2022-06-24 Modernatx, Inc. Pripravci i postupci unosa terapijskih sredstava
MA45052A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
CN116837052A (zh) 2016-09-14 2023-10-03 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
WO2018187590A1 (en) 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
WO2019036683A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
ES2983060T3 (es) 2017-08-18 2024-10-21 Modernatx Inc Variantes de ARN polimerasa
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
CN113795579A (zh) 2019-02-20 2021-12-14 摩登纳特斯有限公司 用于共转录加帽的rna聚合酶变体
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
CA3132975A1 (en) 2019-03-11 2020-09-17 Modernatx, Inc. Fed-batch in vitro transcription process
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
JP2023525936A (ja) * 2020-05-18 2023-06-19 康希諾（上海）生物科技有限公司 ｍＲＮＡ又はｍＲＮＡ組成物、その調製方法及び使用
AU2021294342A1 (en) * 2020-06-26 2023-02-23 Elicio Therapeutics, Inc. Compositions and methods for inducing an immune response against coronavirus
WO2022046583A1 (en) * 2020-08-24 2022-03-03 Phylex Biosciences, Inc. Reagents and methods for preventing, treating or limiting severe acute respiratory syndrome (sars) coronavirus infection
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20220193225A1 (en) * 2020-08-31 2022-06-23 Bruce Lyday Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins
US20230416309A1 (en) * 2020-10-23 2023-12-28 Jiangsu Provincial Center For Disease Control And Prevention (Public Health Research Institute Of Ji Fusion protein and application thereof
CN114517205A (zh) * 2020-11-20 2022-05-20 北京震旦鼎泰生物科技有限公司 融合基因及一种重组新型冠状病毒高效免疫鼎分子dna疫苗及其构建方法和应用
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
EP4277655A1 (en) * 2021-01-15 2023-11-22 ModernaTX, Inc. Variant strain-based coronavirus vaccines
US11524023B2 (en) * 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
EP4308156A1 (en) * 2021-03-15 2024-01-24 ModernaTX, Inc. Therapeutic use of sars-cov-2 mrna domain vaccines
WO2022215036A1 (en) 2021-04-08 2022-10-13 Vaxthera Sas Coronavirus vaccine comprising a mosaic protein
US20240321387A1 (en) 2021-05-04 2024-09-26 BioNTech SE Immunogen selection
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
EP4384212A4 (en) * 2021-08-15 2025-06-25 Dennis R. Burton Undirected mutated mrna vaccine
EP4387592A4 (en) * 2021-08-17 2025-08-06 Univ Monash VACCINE COMPOSITIONS
AU2022333308A1 (en) * 2021-08-24 2024-03-07 Victoria Link Limited Fusion polypeptide
WO2023034991A1 (en) * 2021-09-02 2023-03-09 Kansas State University Research Foundation Mrna vaccine formulations and methods of using the same
CN113527522B (zh) * 2021-09-13 2021-12-21 深圳市瑞吉生物科技有限公司 一种新冠病毒三聚体重组蛋白、DNA、mRNA及应用和mRNA疫苗
CN116064598B (zh) * 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
WO2023060483A1 (zh) * 2021-10-13 2023-04-20 清华大学 多肽-rbd免疫偶联物及其用途
CN118302189A (zh) 2021-10-21 2024-07-05 生物技术欧洲股份公司 冠状病毒疫苗
US20250026793A1 (en) * 2021-10-21 2025-01-23 The University Of Melbourne Chimeric betacoronavirus spike polypeptides
WO2023092069A1 (en) * 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
EP4436984A1 (en) * 2021-11-24 2024-10-02 Flagship Pioneering Innovations VI, LLC Coronavirus immunogen compositions and their uses
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
TW202333780A (zh) 2021-11-29 2023-09-01 德商拜恩技術股份公司 冠狀病毒疫苗
IL288634A (en) * 2021-12-02 2023-07-01 Yeda Res & Dev Improving the translation and protein secretion efficiency of mRNA vaccines
WO2023113094A1 (ko) * 2021-12-16 2023-06-22 주식회사 씨티씨백 면역원성이 증가된 코로나바이러스감염증-19 백신 조성물
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
CN116376942A (zh) * 2021-12-31 2023-07-04 广州国家实验室 mRNA疫苗
WO2023142283A1 (zh) 2022-01-27 2023-08-03 深圳市瑞吉生物科技有限公司 一种新型冠状病毒mRNA疫苗及其制备方法与应用
EP4242308A1 (en) 2022-01-27 2023-09-13 Shenzhen Rhegen Biotechnology Co., Ltd. Sars-cov-2 mrna vaccine, and preparation method therefor and use thereof
WO2023143600A1 (zh) * 2022-01-30 2023-08-03 康希诺生物股份公司 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
CN116554042A (zh) * 2022-01-30 2023-08-08 康希诺生物股份公司 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
CN114213509B (zh) * 2022-02-22 2022-06-10 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗及其用途
CN116726162A (zh) * 2022-03-11 2023-09-12 病毒与疫苗研究中心有限公司 用于呼吸道病毒性疾病的疫苗加强组合物
KR102850225B1 (ko) * 2022-04-07 2025-09-18 엠큐렉스 주식회사 사스-코로나바이러스 2 감염증에 대한 rna 백신
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
EP4604995A1 (en) 2022-10-17 2025-08-27 BioNTech SE Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
CN115960923A (zh) * 2022-11-24 2023-04-14 威瑞生物科技(昆明)有限责任公司 一种包含非人种属调控元件的SARS-COV-2刺突蛋白mRNA及其构建方法与应用
WO2024141784A2 (en) * 2022-12-29 2024-07-04 Popvax Private Limited Broadly protective betacoronavirus vaccines and compositions
CN120435314A (zh) * 2022-12-29 2025-08-05 波普瓦克斯私人有限公司 多靶疫苗和治疗剂
IL322194A (en) * 2023-01-20 2025-09-01 Astrazeneca Ab Nucleic acid molecules
CN117003835A (zh) * 2023-03-17 2023-11-07 成都威斯克生物医药有限公司 抗SARS-CoV-2奥密克戎突变株XBB及其亚型感染的蛋白及疫苗
WO2025027492A1 (en) * 2023-07-31 2025-02-06 Pfizer Inc. Coronavirus antigen variants
GB202416789D0 (en) * 2023-11-15 2025-01-01 BioNTech SE SARS-COV-2 immunogenic compositions
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
WO2026047603A1 (en) * 2024-08-28 2026-03-05 BioNTech SE Sars-cov-2 immunogenic compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513956A (ja) 2014-04-23 2017-06-01 モデルナティーエックス， インコーポレイテッド 核酸ワクチン
WO2018151816A1 (en) 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
ATE490267T1 (de) 2001-06-05 2010-12-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8278063B2 (en) 2007-06-29 2012-10-02 Commonwealth Scientific And Industrial Research Organisation Methods for degrading toxic compounds
DK2205618T3 (en) 2007-09-26 2017-02-20 Intrexon Corp SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION
WO2009075886A1 (en) 2007-12-11 2009-06-18 The Scripps Research Institute Compositions and methods related to mrna translational enhancer elements
BR112012002291A2 (pt) 2009-07-31 2016-11-29 Ethris Gmbh "polirribonucleotídeo com uma sequência que codifica uma proteína ou fragmento de proteína, implante, e, processo para a seleção de sequências de nucleotídeos"
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
US10245229B2 (en) 2012-06-08 2019-04-02 Translate Bio, Inc. Pulmonary delivery of mRNA to non-lung target cells
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
DK2970456T3 (da) 2013-03-14 2021-07-05 Translate Bio Inc Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer
US10130649B2 (en) 2013-03-15 2018-11-20 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
SG11201510747RA (en) 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
KR102399799B1 (ko) 2013-12-30 2022-05-18 큐어백 아게 인공 핵산 분자
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
BR112016021345A8 (pt) * 2014-03-17 2022-07-05 Tapimmune Inc Composições de vacina de molécula de ácido nucleico e usos das mesmas
WO2016138160A1 (en) * 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
EP4286012A3 (en) * 2015-09-17 2024-05-29 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
TW201729835A (zh) * 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
CN116837052A (zh) 2016-09-14 2023-10-03 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
WO2018081638A1 (en) * 2016-10-27 2018-05-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
EP3558356A2 (en) * 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
ES2983060T3 (es) 2017-08-18 2024-10-21 Modernatx Inc Variantes de ARN polimerasa
EP3681514A4 (en) * 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
US10953089B1 (en) * 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CA3170575A1 (en) * 2020-03-06 2021-09-10 Michael Gordon Joyce Vaccines against sars-cov-2 and other coronaviruses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513956A (ja) 2014-04-23 2017-06-01 モデルナティーエックス， インコーポレイテッド 核酸ワクチン
WO2018151816A1 (en) 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Betacoronavirus sp. isolate Wuhan-Hu-1, complete genome.，Database DDBJ/EMBL/GenBank [online]，[retrieved on 2023-09-04]，2020年01月12日，Accession No.MN908947，https://www.ncbi.nlm.nih.gov/nuccore/1791269088?sat=47&satkey=147804071
Nature，2020年02月03日，Vol.579，pp.265-269

Also Published As

Publication number Publication date
JP7832243B2 (ja) 2026-03-17
JP2023153256A (ja) 2023-10-17
JP2023513544A (ja) 2023-03-31
IL295377A (en) 2022-10-01
CA3170150A1 (en) 2021-08-12
CN115551545A (zh) 2022-12-30
JP7443608B2 (ja) 2024-03-05
WO2021159040A9 (en) 2021-11-25
MX2022009707A (es) 2022-09-07
EP4100052A2 (en) 2022-12-14
WO2021159040A2 (en) 2021-08-12
AU2021215938A1 (en) 2022-09-01
WO2021159040A3 (en) 2021-11-04
US20230346914A1 (en) 2023-11-02
KR20220140528A (ko) 2022-10-18
JP2024050973A (ja) 2024-04-10
BR112022015565A2 (pt) 2022-09-27

Similar Documents

Publication Publication Date Title
JP7443608B2 (ja) ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン
US20240299531A1 (en) Therapeutic use of sars-cov-2 mrna domain vaccines
US20240293534A1 (en) Coronavirus glycosylation variant vaccines
US20240285754A1 (en) Mrna vaccines encoding flexible coronavirus spike proteins
US20240358819A1 (en) Pan-human coronavirus domain vaccines
US20230355743A1 (en) Multi-proline-substituted coronavirus spike protein vaccines
JP2024503698A (ja) 変異型株ベースのコロナウイルスワクチン
JP2024503699A (ja) バリアント株ベースのコロナウイルスワクチン
WO2023283642A2 (en) Pan-human coronavirus concatemeric vaccines
JP2024513999A (ja) インフルエンザ－コロナウイルス組み合わせワクチン
JP2024514182A (ja) 呼吸器ウイルス組み合わせワクチン
JP2024514183A (ja) エプスタイン－バーウイルスｍＲＮＡワクチン
JP2023511633A (ja) コロナウイルスｒｎａワクチン
WO2021159130A2 (en) Coronavirus rna vaccines and methods of use
WO2023092069A1 (en) Sars-cov-2 mrna domain vaccines and methods of use
JP2023513073A (ja) 呼吸器系ウイルス免疫化組成物
TW202217000A (zh) Ｓａｒｓ—ｃｏｖ—２ ｍｒｎａ結構域疫苗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230816

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230911

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240207

R150 Certificate of patent or registration of utility model

Ref document number: 7438604

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350